Moderna Inc. — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

2 Recruiting

8 Completed trials

12 Countries active

30 Unique IMPs

100% Results reported

Phase III

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I/II: 1 Phase IV: 1 Phase I (Other): 1 Phase I (FiH): 5

Oversight events:

1 serious breach 8 temporary halts 1 urgent safety measure 2 unexpected events across 4 trials

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cytomegalovirus immunisation 1 Methylmalonic aciduria 1 Influenza 1 Glycogen storage disease type I 1

Top IMPs

All trials

11 total

A study to assess the long-term safety and clinical activity of mRNA-3927 in participants previously enrolled in the mRNA-3927-P101 study Pending

2022-502911-12-00 Phase I/II 3 countries MODIFIED MESSENGER RIBONUCLEIC ACID ENCODING HUMAN PROPIONYL-COENZYME A CARBOXYL…
A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting

2022-502910-10-00 Phase I (FiH) 4 countries MODIFIED MESSENGER RIBONUCLEIC ACID ENCODING HUMAN PROPIONYL-COENZYME A CARBOXYL…
Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting

2022-501997-20-00 Phase I (FiH) 3 countries MODIFIED MRNA ENCODING HUMAN METHYLMALONYL-COENZYME A MUTASE CONTAINING A POLYMO…
A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against S… Ended

2025-523841-82-00 Phase IV 1 country ELASOMERAN
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Phase III 5 countries B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B…
A study to investigate the reactogenicity, safety, and immunogenicity of mRNA-1345 in pregnant women, and safety and immunogenicity in their… Ended

2023-505359-37-00 Phase II 1 country MRNA-1345
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine… Ended

2022-502963-39-00 Phase I (FiH) 4 countries MRNA ENCODING HUMAN GLUCOSE-6-PHOSPHATASE VARIANT S298C; SODIUM CHLORIDE
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended

2022-502022-41-00 Phase I (Other) 3 countries MRNA-1345; MRNA-1365-RSV; N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (D…
A clinical study to evaluate mRNA-3705 in Patients with MMA Ended

2022-502492-32-00 Phase I (FiH) 3 countries MODIFIED MRNA ENCODING HUMAN METHYLMALONYL-COENZYME A MUTASE CONTAINING A POLYMO…
Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended

2023-508820-37-00 Phase III 7 countries MRNA ENCODING HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B, MRNA ENCODING HUMAN CYTOMEGA…
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended

2023-506963-32-00 Phase I (FiH) 3 countries MRNA-3210

Showing 1–11 of 11 trials

← All sponsors A–Z